**Credit for NASW (National Association of Social Workers) is not available for this presentation** Description of Presentation: The rise in GLP-1 agonists consumers as well as expanding indication for use is now spreading more and more into the realm of eating disorders
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
We will provide the necessary guidance throughout the treatment process to help you achieve the best possible outcomes
First, reduced caloric intake means less raw material for muscle protein synthesis
Additionally, using sunscreen and maintaining a healthy skincare routine can optimize results